The estimated Net Worth of Ronnie Morris is at least $4.84 Million dollars as of 17 March 2023. Ronnie Morris owns over 12,382 units of Champions Oncology Inc stock worth over $3,495,633 and over the last 14 years he sold CSBR stock worth over $394. In addition, he makes $1,343,650 as Chief Executive Officer and Director at Champions Oncology Inc.
Ronnie has made over 18 trades of the Champions Oncology Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 12,382 units of CSBR stock worth $50,023 on 17 March 2023.
The largest trade he's ever made was buying 2,710,526 units of Champions Oncology Inc stock on 11 March 2015 worth over $11,031,841. On average, Ronnie trades about 146,660 units every 148 days since 2010. As of 17 March 2023 he still owns at least 858,878 units of Champions Oncology Inc stock.
You can see the complete history of Ronnie Morris stock trades at the bottom of the page.
Dr. Ronnie Morris M.D. serves as Chief Executive Officer, Director of the Company. Dr. Morris previously served as the President and a director of the Company from October 2010 to January 2017. Dr. Morris received his medical degree from the University of Medicine and Dentistry of New Jersey in 1993, completed his residency at the Long Island Jewish Medical Center in 1996, and obtained his certification from the American Board of Internal Medicine in 1996. From 1996 to 2004, Dr. Morris practiced internal medicine and was a managing partner of Prohealth Medical Group in Boca Raton, Florida where, in addition to his personal medical practice of more than 2,500 patients, he managed over 30 physicians in a multi-specialty practice, was responsible for the practice’s financial operations, and coordinated and created ancillary revenue services for the practice. From 2004 to 2006, Dr. Morris was Vice President and Medical Director of AllianceCare Inc. in Boynton Beach, Florida, a company that provides home health care, physical therapy, and doctor “house calls”. In that capacity, Dr. Morris was responsible for the physician house call business, developed new markets, managed and directed 150 employees, tripled revenue and brought his division to profitability. In 2001, in Boca Raton, Florida, Dr. Morris co-founded MDVIP, Inc., a personalized healthcare services company. Until 2009, when MDVIP was acquired by Procter and Gamble Co., Dr. Morris served on MDVIP’s Board of Directors, as Medical Director, and as a member of its executive management team. In those capacities, Dr. Morris conceptualized, developed and helped build MDVIP from a start-up company into a national leader in personalized healthcare services, with a network of 400 doctors in 29 states and 125,000 consumers/patients. Since 2009, Dr. Morris has been a private investor. Dr. Morris’s employment agreement with the Company provides that the Company will nominate him for election as a director for so long as he serves as an executive officer of the Company.
As the Chief Executive Officer and Director of Champions Oncology Inc, the total compensation of Ronnie Morris at Champions Oncology Inc is $1,343,650. There are no executives at Champions Oncology Inc getting paid more.
Ronnie Morris is 54, he's been the Chief Executive Officer and Director of Champions Oncology Inc since 2017. There are 6 older and 3 younger executives at Champions Oncology Inc. The oldest executive at Champions Oncology Inc is Abba Poliakoff, 68, who is the Independent Director.
Ronnie's mailing address filed with the SEC is C/O CHAMPIONS ONCOLOGY, INC., ONE UNIVERSITY PLACE, SUITE 307, HACKENSACK, NJ, 07601.
Over the last 21 years, insiders at Champions Oncology Inc have traded over $9,072,751 worth of Champions Oncology Inc stock and bought 42,104,566 units worth $13,657,266 . The most active insiders traders include Ventures Ix, L.P.Battery In..., Michael Maurice Brown, and Sports Inc Champions. On average, Champions Oncology Inc executives and independent directors trade stock every 76 days with the average trade being worth of $2,196,294. The most recent stock trade was executed by Daniel Newman Mendelson on 12 January 2024, trading 1,000 units of CSBR stock currently worth $6,500.
champions oncology, inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. champions tumorgraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice followed by propagation of the resulting engraftments, or tumorgrafts, in a manner that preserves the biological characteristics of the original human tumor. champions believes that these tumorgrafts, unlike cell line derived xenografts used in tradition testing, closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. the company offers personalized tumorgraft development, drug studies and genome sequencing as part of its personalized oncology solutions ("pos") whereby physicians can evaluate the effects of cancer drugs on their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them
Champions Oncology Inc executives and other stock owners filed with the SEC include: